Holen Sie sich die Stockscreener-App
30.91
0.96%
-0.30
Schlusskurs vom Vortag:
$31.21
Offen:
$31.22
24-Stunden-Volumen:
461.60K
Relative Volume:
0.40
Marktkapitalisierung:
$1.77B
Einnahmen:
$199.89M
Nettoeinkommen (Verlust:
$52.48M
KGV:
36.36
EPS:
0.85
Netto-Cashflow:
$61.15M
1W Leistung:
+5.35%
1M Leistung:
-2.28%
6M Leistung:
+227.78%
1J Leistung:
+159.53%
1-Tages-Spanne:
$30.28
$31.44
1-Wochen-Bereich:
$28.51
$31.44
52-Wochen-Spanne:
$5.35
$38.69
Stoke Therapeutics Inc Stock (STOK) Company Profile
Firmenname
Stoke Therapeutics Inc
Sektor
Branche
Telefon
781-430-8200
Adresse
45 WIGGINS AVENUE, BEDFORD, MA
Vergleichen Sie STOK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
30.91 | 1.78B | 199.89M | 52.48M | 61.15M | 0.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-18 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-03-26 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-07-25 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Fortgesetzt | Canaccord Genuity | Buy |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-10-24 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Eingeleitet | Jefferies | Buy |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-11-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Eingeleitet | UBS | Neutral |
| 2021-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-12-11 | Bestätigt | Needham | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-29 | Eingeleitet | Needham | Buy |
| 2019-12-18 | Eingeleitet | Wedbush | Outperform |
| 2019-11-12 | Eingeleitet | BTIG Research | Buy |
| 2019-10-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Credit Suisse | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Can Stoke Therapeutics (STOK) Translate Natural History Data Into a Competitive Edge for Dravet Therapy? - simplywall.st
Kennondale Capital Management LLC Grows Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Insider Sell: Adrian Krainer Sells 40,472 Shares of Stoke Therap - GuruFocus
Stoke Therapeutics (NASDAQ:STOK) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Stoke Therapeutics (STOK): Evaluating Valuation Following Key Dravet Syndrome Study Results Published in Neurology - simplywall.st
Jefferies Sticks to Their Buy Rating for Stoke Therapeutics (STOK) - The Globe and Mail
FY2025 Earnings Forecast for STOK Issued By Chardan Capital - MarketBeat
Biogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globally - MSN
Stoke Therapeutics Target of Unusually High Options Trading (NASDAQ:STOK) - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Rating Increased to Strong-Buy at Chardan Capital - MarketBeat
(STOK) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Why Stoke Therapeutics Inc. stock remains undervaluedMarket Risk Report & Short-Term High Return Ideas - newser.com
Can Stoke Therapeutics Inc. stock sustain institutional interest2025 Sector Review & Risk Adjusted Buy and Sell Alerts - newser.com
How Stoke Therapeutics Inc. stock valuations compare to rivalsProduct Launch & Verified Momentum Stock Alerts - newser.com
Can Stoke Therapeutics Inc. stock surprise with earnings upsideQuarterly Profit Report & High Conviction Buy Zone Alerts - newser.com
Can Stoke Therapeutics Inc. stock resist sector downturns2025 Top Decliners & Intraday High Probability Alerts - newser.com
Stoke Therapeutics (NASDAQ:STOK) Director Adrian Krainer Sells 40,472 Shares - MarketBeat
Does Stoke Therapeutics Inc. show high probability of reboundJuly 2025 Gainers & Weekly High Return Forecasts - newser.com
Is Stoke Therapeutics Inc. stock a good choice for value investors2025 Sector Review & Weekly High Conviction Ideas - newser.com
Live market analysis of Stoke Therapeutics Inc.July 2025 Gainers & Free Growth Oriented Trading Recommendations - newser.com
Why Stoke Therapeutics Inc. stock attracts high net worth investorsBear Alert & Fast Moving Stock Trade Plans - newser.com
Stoke Therapeutics (NASDAQ:STOK) Trading Up 7.6%Still a Buy? - MarketBeat
Will Stoke Therapeutics Inc. stock maintain momentum in 20252025 Analyst Calls & Risk Managed Investment Signals - newser.com
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - MarketScreener
19,300 Shares in Stoke Therapeutics, Inc. $STOK Purchased by Integrated Quantitative Investments LLC - MarketBeat
Los Angeles Capital Management LLC Makes New $224,000 Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)November 18, 2025 - BioSpace
What technical models suggest about Stoke Therapeutics Inc.’s comeback2025 EndofYear Setup & Verified Trade Idea Suggestions - newser.com
Stoke Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Stoke Therapeutics Director Adrian R. Krainer Sells Over 40,000 Shares - TradingView
Dir Krainer Sells 40,472 ($1.1M) Of Stoke Therapeutics Inc [STOK] - TradingView
[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity - Stock Titan
Could Endpoint Choices in the EMPEROR Trial Reveal a Strategic Shift for Stoke Therapeutics (STOK)? - simplywall.st
A Look at Biogen (BIIB) Valuation Following New Dravet Syndrome Study Results - Yahoo Finance
Finanzdaten der Stoke Therapeutics Inc-Aktie (STOK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
1.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):